Precision Antibiotic Dosing in Older Adults
Part of Infections clinical trials.
This trial tests a personalized way of giving a strong antibiotic (ceftazidime-avibactam) to older adults. Doctors adjust the dose based on your own body's handling of the drug, aiming to make treatment safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You are scheduled to receive ceftazidime-avibactam (an antibiotic) for more than 5 days.
- You have not used ceftazidime-avibactam in the past month.
- You are not on any form of dialysis, and you do not have a history of severe kidney problems (like having a kidney removed, a kidney transplant, a single kidney, or kidney failure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
This study tests whether tailoring the dose of the antibiotic ceftobiprole based on your individual body and kidney function helps treat infections more safely and effectively in older adults.
This trial tests if adjusting ceftazidime (a powerful antibiotic) early on helps treat serious infections better in intensive care patients. You may qualify if you are in the ICU and your doctor is considering starting this antibiotic.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
Hear when a new Ceftazidime-avibactam trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.